BR112015017100A2 - processo para o preparo do agente antitumoral 6-(7-((1-aminociclopropil) metoxi)-6-metoxiquinolin-4-iloxi)-n-metil-1- naftamida e seu cristalino - Google Patents

processo para o preparo do agente antitumoral 6-(7-((1-aminociclopropil) metoxi)-6-metoxiquinolin-4-iloxi)-n-metil-1- naftamida e seu cristalino

Info

Publication number
BR112015017100A2
BR112015017100A2 BR112015017100A BR112015017100A BR112015017100A2 BR 112015017100 A2 BR112015017100 A2 BR 112015017100A2 BR 112015017100 A BR112015017100 A BR 112015017100A BR 112015017100 A BR112015017100 A BR 112015017100A BR 112015017100 A2 BR112015017100 A2 BR 112015017100A2
Authority
BR
Brazil
Prior art keywords
yloxy
methoxy
methyl
naphtamide
aminocyclopropyl
Prior art date
Application number
BR112015017100A
Other languages
English (en)
Inventor
Paul Chen Guoqing
Original Assignee
Advenchen Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201361754516P priority Critical
Application filed by Advenchen Pharmaceuticals Llc filed Critical Advenchen Pharmaceuticals Llc
Priority to PCT/US2014/011948 priority patent/WO2014113616A1/en
Publication of BR112015017100A2 publication Critical patent/BR112015017100A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/02Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/26Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63Esters of sulfonic acids
    • C07C309/64Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66Methanesulfonates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/233Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring

Abstract

resumo “processo para o preparo do agente antitumoral 6-(7-((1-aminociclopropil) metoxi)-6-metoxiquinolin-4- iloxi)-n-metil-1-naftamida e seu cristalino”, por tratar-se a presente invenção de um novo processo para sintetizar 6-(7-((1-aminociclopropil)-metoxi)-6- metoxiquinolin-4-iloxi)-n-metil-1-naftamida (al3810) através da desproteção do substituto benzil 1-((6-metoxi-4-(5-(metilcarbamoil)naftaleno-2-iloxi)quinolin-7-iloxi)- metil)cicloprilcarbamato (fórmula i) sob uma condição ácida fraca ou diluída. uma forma cristalina estável de 6-(7-((1-aminociclopropil)-metoxi)-6-metoxiquinolin-4- iloxi)-n-metil-1-naftamida foi também preparada. 1/1
BR112015017100A 2013-01-18 2014-01-17 processo para o preparo do agente antitumoral 6-(7-((1-aminociclopropil) metoxi)-6-metoxiquinolin-4-iloxi)-n-metil-1- naftamida e seu cristalino BR112015017100A2 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201361754516P true 2013-01-18 2013-01-18
PCT/US2014/011948 WO2014113616A1 (en) 2013-01-18 2014-01-17 Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline

Publications (1)

Publication Number Publication Date
BR112015017100A2 true BR112015017100A2 (pt) 2017-07-11

Family

ID=51210076

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015017100A BR112015017100A2 (pt) 2013-01-18 2014-01-17 processo para o preparo do agente antitumoral 6-(7-((1-aminociclopropil) metoxi)-6-metoxiquinolin-4-iloxi)-n-metil-1- naftamida e seu cristalino

Country Status (18)

Country Link
US (1) US9783498B2 (pt)
EP (1) EP2945931A4 (pt)
JP (1) JP2016506917A (pt)
KR (1) KR102275034B1 (pt)
CN (2) CN104936946A (pt)
AU (1) AU2014207482A1 (pt)
BR (1) BR112015017100A2 (pt)
CA (1) CA2896898A1 (pt)
EA (1) EA201591205A1 (pt)
HK (2) HK1213563A1 (pt)
IL (1) IL239877A (pt)
MA (1) MA38274A1 (pt)
MX (1) MX2015008543A (pt)
PH (1) PH12015501571A1 (pt)
RU (1) RU2015127211A (pt)
SG (1) SG11201505389WA (pt)
WO (1) WO2014113616A1 (pt)
ZA (1) ZA201505043B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105311030B (zh) 2014-06-06 2020-03-24 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物
CN105311029A (zh) 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
US10112945B2 (en) 2014-07-14 2018-10-30 Advenchen Pharmaceuticals, Nanjing Ltd. Fused quinoline compunds as PI3K, mTOR inhibitors
AU2015360095B2 (en) 2014-12-09 2020-02-27 Advenchen Laboratories Nanjing Ltd Quinoline derivative against non-small cell lung cancer
US9751859B2 (en) * 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
WO2017011363A1 (en) 2015-07-11 2017-01-19 Advenchen Pharmaceuticals, LLC Fused quinoline compunds as pi3k/mtor inhibitors
CN107296811A (zh) 2016-04-15 2017-10-27 正大天晴药业集团股份有限公司 一种用于治疗胃癌的喹啉衍生物
EP3766870A4 (en) 2018-03-02 2021-12-22 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. CRYSTAL OF A COMPOUND TO BE USED AS A KINASE C-MET INHIBITOR, PROCESS OF PREPARATION AND USE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
US8148532B2 (en) * 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
IT1393351B1 (it) * 2009-03-16 2012-04-20 Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi
US8664244B2 (en) * 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
WO2013081154A1 (ja) * 2011-12-02 2013-06-06 味の素株式会社 キナーゼ阻害剤の副作用低減剤
ES2813869T3 (es) * 2012-11-08 2021-03-25 Clearside Biomedical Inc Métodos para el tratamiento de la enfermedad ocular en sujetos humanos

Also Published As

Publication number Publication date
MA38274A1 (fr) 2017-02-28
PH12015501571A1 (en) 2015-10-05
KR20150108871A (ko) 2015-09-30
CN111454206A (zh) 2020-07-28
IL239877A (en) 2018-07-31
ZA201505043B (en) 2017-11-29
SG11201505389WA (en) 2015-08-28
CN104936946A (zh) 2015-09-23
KR102275034B1 (ko) 2021-07-12
IL239877D0 (en) 2015-08-31
AU2014207482A1 (en) 2015-08-13
EP2945931A1 (en) 2015-11-25
WO2014113616A1 (en) 2014-07-24
CA2896898A1 (en) 2014-07-24
MX2015008543A (es) 2015-11-16
EP2945931A4 (en) 2016-10-12
EA201591205A1 (ru) 2015-12-30
HK1213563A1 (zh) 2016-07-08
US9783498B2 (en) 2017-10-10
US20150353496A1 (en) 2015-12-10
RU2015127211A (ru) 2017-03-03
HK1217328A1 (zh) 2017-01-06
JP2016506917A (ja) 2016-03-07

Similar Documents

Publication Publication Date Title
BR112015017100A2 (pt) processo para o preparo do agente antitumoral 6-(7-((1-aminociclopropil) metoxi)-6-metoxiquinolin-4-iloxi)-n-metil-1- naftamida e seu cristalino
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
BR112017010354A2 (pt) compostos de triazolopirimidina e usos dos mesmos
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
BR112015022861A2 (pt) inibidores de bromodomínio
TR201900038T4 (tr) GPR6'nın tetrahidropiridopirazin modülatörleri.
BR112015020350A2 (pt) derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
CO2018000795A2 (es) Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il)propanoico sustituido
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
NZ705213A (en) C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
EA201492285A1 (ru) Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar)
BR112015028452A2 (pt) agonistas do receptor somastatina subtipo 4 (sstr4)
EA201690072A1 (ru) Состав, содержащий гиполипидемическое средство
BR112016011170A8 (pt) derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica
TW201613603A (en) Pharmaceutical preparation
CY1119581T1 (el) Παραγωγα πυριδινυλο- και πυραζινυλο-μεθυλοξυ-αρυλιου χρησιμα ως αναστολεις της τυροσινης κινασης σπληνας (syk)
BR112013030264A2 (pt) ácidos acéticos de benzociclohepteno
MX2016007810A (es) Derivados de n1-(3,3,3-trifluoro-2-hidroxo-2-metilpropionil)-piper idina como inhibidores de piruvato deshidrogenasa cinasa.
MX2017015662A (es) Procesos para la preparacion de derivados acidos de n-acetilgalactosamina (galnac).
WO2014145887A8 (en) Benzimidazole derivatives and uses thereof
EA201891866A1 (ru) N,N-ДИМЕТИЛ-3-[[5-(3-МЕТИЛ-2-ОКСО-1-ТЕТРАГИДРОПИРАН-4-ИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-8-ИЛ)-2-ПИРИДИЛ]ОКСИ]ПРОПАН-1-АМИНОКСИД В КАЧЕСТВЕ МОДУЛЯТОРА АТМ-КИНАЗЫ (МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ) ДЛЯ ЛЕЧЕНИЯ РАКА
MX2018008966A (es) Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo.
EA201600002A1 (ru) Производные пролекарства замещенных триазолопиридинов

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]